CN103103251A - Kit for detecting FLT3-ITD (Fms-like tyrosine kinase 3-internal tandem duplication) gene mutation by using fluorescence PCR (Polymerase Chain Reaction) capillary electrophoresis - Google Patents
Kit for detecting FLT3-ITD (Fms-like tyrosine kinase 3-internal tandem duplication) gene mutation by using fluorescence PCR (Polymerase Chain Reaction) capillary electrophoresis Download PDFInfo
- Publication number
- CN103103251A CN103103251A CN2011103617071A CN201110361707A CN103103251A CN 103103251 A CN103103251 A CN 103103251A CN 2011103617071 A CN2011103617071 A CN 2011103617071A CN 201110361707 A CN201110361707 A CN 201110361707A CN 103103251 A CN103103251 A CN 103103251A
- Authority
- CN
- China
- Prior art keywords
- seq
- itd
- flt3
- test kit
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000003752 polymerase chain reaction Methods 0.000 title claims abstract description 9
- 238000005251 capillar electrophoresis Methods 0.000 title abstract description 12
- 206010064571 Gene mutation Diseases 0.000 title description 2
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 title 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 238000006243 chemical reaction Methods 0.000 claims abstract description 17
- 210000004369 blood Anatomy 0.000 claims abstract description 8
- 239000008280 blood Substances 0.000 claims abstract description 8
- 239000012634 fragment Substances 0.000 claims abstract description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 6
- 238000001962 electrophoresis Methods 0.000 claims abstract description 6
- 208000032839 leukemia Diseases 0.000 claims abstract description 5
- 238000012360 testing method Methods 0.000 claims description 33
- 238000003908 quality control method Methods 0.000 claims description 12
- 238000012408 PCR amplification Methods 0.000 claims description 11
- 230000003321 amplification Effects 0.000 claims description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 9
- 239000012295 chemical reaction liquid Substances 0.000 claims description 8
- 238000013016 damping Methods 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 5
- 238000011144 upstream manufacturing Methods 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 230000004087 circulation Effects 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 abstract description 20
- 238000000034 method Methods 0.000 abstract description 18
- 238000004393 prognosis Methods 0.000 abstract description 16
- 238000001514 detection method Methods 0.000 abstract description 11
- 238000004458 analytical method Methods 0.000 abstract description 7
- 230000035772 mutation Effects 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 2
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 abstract 2
- 238000004806 packaging method and process Methods 0.000 abstract 2
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000013642 negative control Substances 0.000 abstract 1
- 239000013641 positive control Substances 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 30
- 239000000523 sample Substances 0.000 description 21
- 230000008859 change Effects 0.000 description 20
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 11
- 101100335080 Homo sapiens FLT3 gene Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 238000007400 DNA extraction Methods 0.000 description 6
- 238000011068 loading method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 108700024394 Exon Proteins 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000011242 molecular targeted therapy Methods 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to a kit for detecting ITD (internal tandem duplication) mutation in an FLT3 (Fms-like tyrosine kinase 3) gene juxtamembrane domain and in particular relates to a kit for detecting the FLT3-ITD in a clinical sample by using a fluorescence PCR (Polymerase Chain Reaction) capillary electrophoresis technology. The kit mainly comprises a PCR amplified reaction solution, a negative control product, a positive control product, a plurality of sealed reagent bottles or pipes which cover the kit as well as packaging boxes which are used for separating and concentratively packaging the reagent bottles or pipes, and the size and gene dosage of each amplified fragment are determined by using an electrophoresis method. The kit disclosed by the invention has high sensitivity and specificity in terms of detection and analysis of the FLT3-ITD in a whole blood or marrow sample and can be widely applied to the fields of judgment prognosis and guide treatment of leukemia and resurgence prevention of diseases.
Description
Technical field
The present invention relates to detect sequence internal series-connection repetition (the internal tandem duplications of FLT3 (Fms-like tyrosine kinase 3) gene membrane-proximal region, ITD) test kit of sudden change particularly relates to the test kit that detects FLT3-ITD in clinical sample with the fluorescent PCR capillary electrophoresis technique.Because this test kit has very high sensitivity and specificity to the determination and analysis of the FLT3-ITD in whole blood or marrow sample, can be widely used in the leukemia judging prognosis, a plurality of fields such as guiding treatment and predictive disease recurrence.
Background technology
FLT3 (Fms-like tyrosine kinase 3) is a member in III receptor family tyrosine kinase, and its sudden change is closely related with leukemic generation.FLT3 and its part (FL) play important regulating effect in the propagation of hematopoietic stem/progenitor and differentiation.FL is combined a series of Cellular Signaling Transduction Mediated approach of mediation with the extracellular domain of FLT3, regulate cell proliferation and activation.When the FLT3 producer suddenlys change, can cause the non-ligand dependent phosphorylation of FLT3, destroy propagation, differentiation and the apoptosis of normal plasma cell.The FLT3 sudden change has two kinds of forms: a kind of for occurring in sequence internal series-connection repetition (the internal tandem duplications of FLT3 gene membrane-proximal region, ITD), be called the FLT3-ITD sudden change, all there are polymorphism in the size of ITD and position, typical ITD is positioned at the 14th exon, also can involve the 14th intron and the 15th exon; A kind of for occurring in the point mutation of Tyrosylprotein kinase structural region, be called the FLT3-TKD sudden change.The FLT3-ITD sudden change that studies show that relevant for the FLT3-ITD sudden change at present the most often appears at acute myelocytic leukemia (acute myeloid leukemia, AML) in the patient, mutation rate is 15%～35%, secondly be myelodysplastic syndrome (myelodysplastic syndromes, MDS), mutation rate is about 2%～5%.FLT3-ITD is incidence extremely low (lower than 1%) in acute lymphoblastic leukemia (ALL) patient, and not yet finds the FLT3-ITD sudden change in chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), multiple myeloma, one-tenth human body cell leukemia.
AML is one group of malignant hematologic disease that originates from hemopoietic stem cell, has height heterogeneity.In the many factors that affects AML prognosis risk level, cytogenetics has been considered to most important independent prognostic factor, and some specific stain body chromosome abnormalities not only become the important symbol thing in the AML diagnosis, and often is considered to the sign of judging prognosis.It is abnormal that but about 40%～50% AML patient does not detect karyotype, and these patient's prognosis variations are larger, and survival rate 24%～42% in 5 years.Become so seek the normal AML patient's of caryogram prognosis molecule sign the focus that people pay close attention to.Application along with the Molecular genetic test method, scholars find that there is heterogeneity in the AML patient of normal karyotype, the abnormal expression that comprises transgenation or some specific gene, providing according to the FLT3 transgenation for AML patient's further prognosis classification and molecular targeted therapy is one of molecular marker that affects AML patient's prognosis of having found, can be used as the individual index of AML patient's prognosis mala.FLT3-ITD sudden change is modal a kind of mutation type in AML patient, and approximately there is the FLT3-ITD sudden change in 15%～35%AML case, and there is the FLT3-TKD sudden change in 7% the AML case of also having an appointment in addition.It is irrelevant with the AML prognosis that but most of research at present thinks that FLT3-TKD suddenlys change, and the FLT3-ITD sudden change is fallen ill with AML and it is closely related to develop, and is an important independent prognostic factor.The FLT3-ITD positive patient has than particular features or clinic, and the targeted therapy that is directed at present this sudden change has also entered different clinical experimental stages.And, also there is difference in different I TD patient's prognosis, this and ITD-AR (internal tandem allelic ratio, internal series-connection repetition allelotrope ratio) value is relevant, be ITD:WT (FLT3 wild type gene) ratio, the ITD-AR value increases may cause prognosis mala, so the ITD-AR value is also AML patient's very strong independent prognostic factor.
MDS patient FLT3-ITD sudden change is than the patient who there is no sudden change, the probability that the FLT3-ITD positive patient transfers AML to has the trend of increasing, progress has shortening trend for the time of AML, and shorten overall lifetime, after MDS transfers AML to, the FLT3-ITD positive rate increases, so FLT3-ITD is the high risk factor that MDS is converted into AML, is the prognosis mala factor.
To sum up, FLT3-ITD can be used as the individual index of AML and MDS patient's prognosis mala, transgenation detects and can help judging prognosis to FLT3-ITD, is used for guiding treatment, judgement curative effect and palindromia, and long-term survival rate and the life quality that increases the patient had very important meaning.
FLT3-ITD detection in Gene Mutation test kit (fluorescent PCR capillary electrophoresis) provides a kind of method of rapid detection FLT3-ITD transgenation.Present method at 14 exons of FLT3-ITD generation and the two ends design upstream and downstream primer of 15 exons, for the DNA sample that the FLT3-ITD transgenation occurs, the amplified production greater than normal fragment will occur respectively according to PCR design of primers principle.Present method determines whether to exist the FLT3-ITD transgenation by the length that capillary electrophoresis method detects the PCR product, and can calculate the ITD-AR value by software analysis, provide theoretical foundation to clinical diagnosis, prognosis judgement and molecular targeted therapy for AML and MDS.Compare common agarose gel electrophoresis, the method is sensitiveer, and can accurately judge clip size and the gene dosage of sudden change band.
Summary of the invention
The purpose of this invention is to provide a kind of test kit that uses the fluorescent PCR capillary electrophoresis technique to detect FLT3-ITD transgenation in the leukemia clinical sample.This test kit uses the ITD zone of PCR method amplification FLT3 by extracting the DNA of blood samples of patients or marrow, then uses the fluorescent PCR capillary electrophoresis technique that ITD clip size and dosage are detected.
In order to realize the present invention, we have adopted following technical scheme:
(1) use suitable foranalysis of nucleic acids software known FLT3 gene nucleotide series is carried out homology relatively and find out on the basis of homology segment, further use suitable primer-design software (for example Primer 3) to select and the design oligonucleotides primer.14 exons that occur at FLT3-ITD due to designed primer and the two ends of 15 exons, and there is no homology with the nucleotide sequence of other genetic expression mRNA, do not comprise any common endonuclease yet, so false negative and the false positive of having avoided FLT3-ITD to detect have improved the reliability and the accuracy that detect;
(2) use the synthetic required Oligonucleolide primers of DNA synthesizer, process with carrying out the ammonia solution after molecular sieve and fast protein liquid chromatography method (FPLC) purifying.Same synthetic required primer sequence, after the ammonia solution is processed respectively at the 6-FAM amidite of its 5 ' end mark as fluorescence generation group (reporter group).With the fluorescently-labeled primer of FPLC purification by chromatography.Primer and the probe that then, can use polyacrylamide gel (20%) electrophoretic method under Denaturing and spectrophotometry physical characterization to be synthesized;
(3) extract DNA from the peripheral blood that derives from the experimenter or marrow, then use the PCR reaction system that it is increased;
(4) provide and comprise (a) sample to be checked, (b) hot resistant DNA polymerase and (c) amplification reaction system of 2-deoxynucleoside triphosphate (dNTPs), and comprise the forward primer that (d) can be combined with article one complementary strand of double-stranded target polynucleotide to be checked, the reverse primer that (e) can be combined with the second complementary strand of double-stranded target polynucleotide to be checked.By the said target polynucleotide of one or many PCR amplification; By the fragment length of fluorescent PCR capillary electrophoresis technique with the detection target polynucleotide.
The test kit that fluorescent PCR capillary electrophoresis technique provided by the present invention detects FLT3-ITD in clinical sample comprises: (1) pcr amplification reaction liquid, negative quality control product, positive quality control product and a plurality of reagent bottles or the pipe that seal, (2) separate and concentrate the packing box of these reagent bottles of packing or pipe, (3) determine size and the gene dosage of amplified fragments with electrophoretic method.
A preferred embodiment of the present invention, wherein pcr amplification reaction liquid comprises that 5 ' end is combined with forward primer, reverse primer, dNTPs, hot resistant DNA polymerase, PCR damping fluid and the water of fluorescence generation group, be characterised in that the primer sequence that uses is respectively: 5 '-FAM-TCTCCTCTTCATTGTCGTTTTA-3 ' (SEQ ID NO:1), 5 '-ATGGTGAGTACGTGCATTTTA-3 ' (SEQ ID NO:2), SEQ ID NO:1 wherein, SEQ ID NO:2 coupling can detect FLT3-ITD together.
Another preferred embodiment of the present invention, the primer sequence that can also use in pcr amplification reaction liquid is respectively: 5 '-FAM-TTCATTATTCTTTCCTCTATCTGC-3 ' (SEQ ID NO:3), 5 '-TGTTGCGTTCATCACTTTTC-3 ' (SEQ ID NO:4), SEQ ID NO:3 wherein, SEQ ID NO:4 coupling can detect FLT3-ITD together.
Another preferred embodiment of the present invention, the primer sequence that can also use in pcr amplification reaction liquid is respectively: 5 '-FAM-AACTGCCTATTCCTAACTGACTC-3 ' (SEQ ID NO:5), 5 '-TCCATAAGCTGTTGCGTTC-3 ' (SEQ ID NO:6), SEQ ID NO::5 wherein, SEQ ID NO:6 coupling can detect FLT3-ITD together.
Another preferred embodiment of the present invention, the primer sequence that can also use in pcr amplification reaction liquid is respectively: 5 '-FAM-GCCAGCTACAGATGGTACAGG-3 ' (SEQ ID NO:7), 5 '-AGCATTTTGACGGCAACC-3 ' (SEQ ID NO:8), wherein SEQ ID NO:7 and SEQ ID NO:8 coupling can detect FLT3-ITD together.
A preferred embodiment of the present invention, pcr amplification reaction liquid wherein is characterised in that in the PCR damping fluid of every 25 microlitres to add 2 Taq of unit enzymes that damping fluid comprises 10mM Tris-HCl (pH8.0), 150mM KCl, 3mM MgCl
2
Another preferred embodiment of the present invention, wherein the pcr amplification reaction system is by PCR damping fluid, hot resistant DNA polymerase, dNTPs, primer forms, the combined sequence that it is characterized in that primer is SEQ ID NO:1 and SEQ ID NO:2, or SEQ ID NO:3 and SEQ ID NO:4, or SEQ ID NO:5 and SEQ ID NO:6, or SEQ ID NO:7 and SEQ ID NO:8.
A preferred embodiment of the present invention, wherein negative quality control product is deionized water, positive quality control product is the recombinant plasmid that carries the FLT3-ITD sequence, plasmid is formed by commercially available carrier cloning structure by the PCR product of upstream and downstream primer amplification, the combined sequence of the upstream and downstream primer that uses can be SEQ ID NO:1 and SEQ ID NO::2, or SEQ ID NO:3 and SEQ ID NO::4, or SEQ ID NO:5 and SEQ ID NO:6, or SEQ ID NO:7 and SEQ ID NO:8.
A preferred embodiment of the present invention; come FLT3 normal gene and FLT3-ITD and dosage variation in analyzing samples according to composite amplification product clip size; any method that can the separating acid fragment size is for example filtered; high performance liquid chromatography; electrophoresis; the methods such as affine collection all can be used for the present invention, wherein separate by the method for gel electrophoresis and quantitatively, preferably use capillary electrophoresis to separate FLT3 normal gene and FLT3-ITD.
A preferred embodiment of the present invention can FLT3 normal gene quantitative according to the accumulative total fluorescent value of primer extension product and the relative quantity of FLT3-ITD, and analyzes the ITD-AR value by calculating FLT3 normal gene and FLT3-ITD relative dosage.
A preferred embodiment of the present invention, wherein the sample to be checked of test kit can be selected from but be not limited to leukaemic's clinical sample.
A preferred embodiment of the present invention, wherein the target polynucleotide of test kit is from the FLT3 gene.
A preferred embodiment of the present invention, wherein the nucleic acid amplification system of test kit adopts polymerase chain reaction, and the circulation of said amplified reaction is that the polymerase chain reaction of repetition 30-50 time circulates.
What deserves to be explained is especially, in order to ensure the accuracy of FLT3-ITD detection method of the present invention, we also use the recombinant plasmid that carries the FLT3-ITD sequence as positive quality control product.By these positive quality control product, use test kit of the present invention to carry out under the same conditions Parallel testing, with detection precision and the accuracy of further checking test kit of the present invention, and as the additional quality control standard of production test kit of the present invention.
Present technique compared with prior art, advantage is: height 1. is quick on the draw, 2. DNA concentration can detect when being 10ng/ μ l can carry out accurate quantification to gene in conjunction with capillary electrophoresis and 3. can carry out analytic statistics 4. under a large amount of wild type genes exist to mutated genes and wild type gene ratio, also can detect the low frequency mutated genes.
Description of drawings
Fig. 1 shows a normal male sample multiplex amplification product electrophorogram.In figure, to be about the blue band of 330bp be the amplified production of a normal male sample to clip size.
Fig. 2 shows a normal female sample multiplex amplification product electrophorogram.In figure, to be about the blue band of 330bp be the amplified production of a normal female sample to clip size.
Fig. 3 shows a male sex AML patient's FLT3-ITD sample amplified production electrophorogram.In figure, clip size is about two blue bands of 330bp and 360bp, shows a male sex AML patient's FLT3-ITD sample amplified production.
Fig. 4 shows a women AML patient's FLT3-ITD sample amplified production electrophorogram.In figure, clip size is about two blue bands of 330bp and 360bp, shows a women AML patient's FLT3-ITD sample amplified production.
Fig. 5 shows the electrophorogram of amplified production of the FLT3-ITD of a MDS clinical samples.In figure, clip size is about two blue bands of 330bp and 360bp, the electrophorogram of the amplified production of the FLT3-ITD of a MDS clinical samples of demonstration.
Embodiment
The following example is intended to illustrate rather than limit the present invention.
Embodiment 1: detection kit and use thereof
1, preparation comprises the test kit of following moiety: ITD PCR reaction solution A (including SEQ ID NO:1 and SEQ ID NO::2) (500 μ l/ pipe), ITD PCR reaction solution B (75 μ l/ pipe), ITD positive quality control product (50 μ l/ pipe), negative quality control product (50 μ l/ pipe).
2, collection of specimens, transport and preserve:
(1) collection of specimens: sample is peripheral blood or marrow.Extract person under inspection's venous blood or marrow 3-5ml, inject the Glass tubing that contains EDTA (disodium ethylene diamine tetraacetate) or sodium citrate anticoagulant, put upside down gently immediately Glass tubing and mix 5～10 times, make the abundant mixing of antithrombotics and venous blood.
(2) preserve: can detect immediately, preserve a week for 4 ℃ ,-20 ℃ of preservation perives can reach 1 year.
(3) transportation: sample transports and should adopt 0 ℃ of curling stone.
3, detecting step and interpretation of result:
Qiagen DNA extraction test kit is used in the DNA extraction suggestion.
(1) get 200 μ l peripheral bloods or marrow to the 1.5ml centrifuge tube.
(2) add the proteolytic enzyme of 20 μ l.
(3) add the Buffer AL of 200 μ l, vibrated 15 seconds.
(4) 56 ℃ of incubations 10 minutes.
(5) add 200 μ l ethanol, vibrated 15 seconds.
(6) mixed solution is sucked QIAamp Mini spin column, centrifugal 1 minute of 6000g.
(7) inner prop is put into a new sleeve pipe, added the Buffer AW1 of 500 μ l, centrifugal 1 minute of 6000g.
(8) inner prop is put into a new sleeve pipe, added the Buffer AW2 of 500 μ l, centrifugal 1 minute of 6000g.
(9) inner prop is put into a new 1.5ml centrifuge tube, centrifugal 1 minute of maximum centrifugal speed.
(10) add the Buffer AE of 200 μ l, standing 1 minute of room temperature, centrifugal 1 minute of 6000g.
(11) obtain 200 μ l DNA solutions
The QF-PCR operation steps:
1, for each PCR reaction system, mixing following composition is 25ul to cumulative volume.The yin and yang attribute contrast is set.
2, PCR reaction conditions: 95 ℃ of denaturations 15 minutes, then 94 ℃ 30 seconds, 62 ℃ 30 seconds, 72 ℃ 30 seconds, totally 30 circulations; Last 72 ℃ 5 minutes.
The amplified production electrophoresis
For each analysis, 1ul PCR product and 13.5ul Hi-DiTM formamide, 0.5ul GeneScan ROX-500Size standard mix.95 ℃ of heat denatured mixtures 5 minutes.Placed at least 1 minute on ice.Instantaneous centrifugal mixture.Loading ABI310/ABI3100 genetic analyzer, then application software is carried out interpretation of result.Collection of illustrative plates such as Fig. 1 as a result, Fig. 2, Fig. 3, Fig. 4, shown in Figure 5.Fig. 1 wherein, Fig. 2 is the interpretation of result collection of illustrative plates of normal male and normal female.
Embodiment 2: by QF-PCR increase FLT3 site detecting AML patient's FLT3-ITD
From AML patient's blood or sample of bone marrow, carry out the DNA extraction purifying according to the standard program of Qiagen DNA extraction test kit.The ITD PCR reaction solution A, the ITD PCR reaction solution B that provide in test kit are provided carry out amplified reaction and loading analysis according to test kit detection rules.Analysis collection of illustrative plates such as Fig. 3 of loading result, Fig. 4.As shown in the figure, wild-type and ITD site on the FLT3 gene.Produce the ITD sudden change at the FLT3 gene, the amplified band greater than wild-type fragment can occur.Thereby can rapid detection FLT3-ITD.
Embodiment 3: by QF-PCR increase FLT3 site detecting MDS patient's FLT3-ITD
From MDS patient's blood or sample of bone marrow, carry out the DNA extraction purifying according to the standard program of Qiagen DNA extraction test kit.The ITD PCR reaction solution A, the ITD PCR reaction solution B that provide in test kit are provided carry out amplified reaction and loading analysis according to test kit detection rules.Analysis collection of illustrative plates such as Fig. 5 of loading result.As shown in the figure, wild-type and ITD site on the FLT3 gene.Produce the ITD sudden change at the FLT3 gene, the amplified band greater than wild-type fragment can occur.Thereby can rapid detection FLT3-ITD.
Above content is in conjunction with concrete preferred implementation further description made for the present invention, can not assert that concrete enforcement of the present invention is confined to these explanations.For the general technical staff of the technical field of the invention, without departing from the inventive concept of the premise, can also make some simple deduction or replace, all should be considered as belonging to protection scope of the present invention.
Claims (6)
1. the test kit of FLT3-ITD in a test sample, test kit comprises: (1) pcr amplification reaction liquid, negative quality control product, positive quality control product and a plurality of reagent bottles or the pipe that seal, (2) separate and concentrate the packing box of these reagent bottles of packing or pipe, wherein pcr amplification reaction liquid comprises that 5 ' end is combined with the forward primer of fluorescence generation group, reverse primer, dNTPs, hot resistant DNA polymerase, PCR damping fluid and water, (3) determine size and the gene dosage of amplified fragments with electrophoretic method, it is characterized in that forward and reverse primer of using sequence can for:
5’-FAM-TCTCCTCTTCATTGTCGTTTTA-3’、5′-ATGGTGAGTACGTGCATTTTA-3′；
5’-FAM-TTCATTATTCTTTCCTCTATCTGC-3’、5′-TGTTGCGTTCATCACTTTTC-3′；
5’-FAM-AACTGCCTATTCCTAACTGACTC-3’、5’-TCCATAAGCTGTTGCGTTC-3’；
5’-FAM-GCCAGCTACAGATGGTACAGG-3’、5’-AGCATTTTGACGGCAACC-3’。
2. according to claim 1 test kit, be further characterized in that the PCR damping fluid comprises 10mM Tris-HCl (pH8.0), 150mM KCl, 3mM MgCl
2, add 2 Taq of unit enzymes in the PCR damping fluid of every 25 microlitres.
3. according to claim 1 test kit, be further characterized in that the pcr amplification reaction system is by PCR damping fluid, hot resistant DNA polymerase, dNTPs, primer forms, the combined sequence that it is characterized in that primer is SEQ ID NO:1 and SEQ ID NO:2, or SEQ ID NO:3 and SEQ ID NO:4, or SEQ ID NO:5 and SEQ ID NO:6, or SEQ ID NO:7 and SEQ ID NO:8.
4. according to claim 1 test kit, be further characterized in that positive quality control product is the recombinant plasmid that carries the FLT3-ITD sequence, plasmid is formed by commercially available carrier cloning structure by the PCR product of upstream and downstream primer amplification, the combined sequence of the upstream and downstream primer that uses can be SEQ ID NO:1 and SEQ ID NO:2, or SEQ ID NO:3 and SEQ ID NO:4, or SEQ ID NO:5 and SEQ ID NO:6, or SEQ ID NO:7 and SEQ ID NO:8.
5. according to claim 1 test kit is further characterized in that the nucleic acid amplification system of test kit adopts polymerase chain reaction, and the circulation of said amplified reaction is that the polymerase chain reaction of repetition 30-50 time circulates.
6. according to claim 1 test kit, be further characterized in that institute's test sample is the leukemia clinical samples such as whole blood or marrow.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103617071A CN103103251A (en) | 2011-11-15 | 2011-11-15 | Kit for detecting FLT3-ITD (Fms-like tyrosine kinase 3-internal tandem duplication) gene mutation by using fluorescence PCR (Polymerase Chain Reaction) capillary electrophoresis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103617071A CN103103251A (en) | 2011-11-15 | 2011-11-15 | Kit for detecting FLT3-ITD (Fms-like tyrosine kinase 3-internal tandem duplication) gene mutation by using fluorescence PCR (Polymerase Chain Reaction) capillary electrophoresis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103103251A true CN103103251A (en) | 2013-05-15 |
Family
ID=48311442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103617071A Pending CN103103251A (en) | 2011-11-15 | 2011-11-15 | Kit for detecting FLT3-ITD (Fms-like tyrosine kinase 3-internal tandem duplication) gene mutation by using fluorescence PCR (Polymerase Chain Reaction) capillary electrophoresis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103103251A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160056841A (en) * | 2014-11-12 | 2016-05-20 | 가톨릭대학교 산학협력단 | Method for quantitative analysis of FLT3 gene mutation and kit |
| CN108676876A (en) * | 2018-05-23 | 2018-10-19 | 苏州锐讯生物科技有限公司 | primer group for detecting mutant type F L T3-ITD based on digital PCR and application thereof |
| CN110241200A (en) * | 2019-06-18 | 2019-09-17 | 苏州大学附属第一医院 | High-sensitivity detection method and kit for FLT3-ITD mutation |
| CN110511983A (en) * | 2019-08-07 | 2019-11-29 | 南京实践医学检验有限公司 | Method based on capillary electrophoresis quantitative detection FLT3-ITD gene mutation |
| CN111433374A (en) * | 2017-12-01 | 2020-07-17 | 生命科技股份有限公司 | Method, system and computer readable medium for detecting tandem repeat region |
| CN111719005A (en) * | 2020-06-29 | 2020-09-29 | 天津拓瑞医药科技有限公司 | PCR detection method for mycoplasma feline haemophilus |
| CN113718020A (en) * | 2021-09-13 | 2021-11-30 | 广东永诺医疗科技有限公司 | Primer-probe combination and kit for detecting internal tandem repeat mutation of human leukemia FLT3 gene and application of primer-probe combination and kit |
| CN117568455A (en) * | 2024-01-03 | 2024-02-20 | 杭州宏望医学检验实验室有限公司 | Primer combinations, kits and methods for detecting leukemia fusion genes based on capillary electrophoresis fragment analysis |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006048274A1 (en) * | 2004-11-04 | 2006-05-11 | Roche Diagnostics Gmbh | Flt3 gene expression profiling |
| US20070292970A1 (en) * | 2003-11-04 | 2007-12-20 | Martin Dugas | Method for Distinguishing Aml-Specific Flt3 Length Mutations From Tkd Mutations |
| CN102007408A (en) * | 2008-02-28 | 2011-04-06 | 俄亥俄州立大学研究基金会 | Microrna signatures associated with cytogenetics and prognosis in acute myeloid leukemia (aml) and uses thereof |
| CN102186995A (en) * | 2008-10-17 | 2011-09-14 | 奎斯特诊断投资公司 | Detection of npm1 nucleic acid in acellular body fluids |
-
2011
- 2011-11-15 CN CN2011103617071A patent/CN103103251A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070292970A1 (en) * | 2003-11-04 | 2007-12-20 | Martin Dugas | Method for Distinguishing Aml-Specific Flt3 Length Mutations From Tkd Mutations |
| WO2006048274A1 (en) * | 2004-11-04 | 2006-05-11 | Roche Diagnostics Gmbh | Flt3 gene expression profiling |
| CN102007408A (en) * | 2008-02-28 | 2011-04-06 | 俄亥俄州立大学研究基金会 | Microrna signatures associated with cytogenetics and prognosis in acute myeloid leukemia (aml) and uses thereof |
| CN102186995A (en) * | 2008-10-17 | 2011-09-14 | 奎斯特诊断投资公司 | Detection of npm1 nucleic acid in acellular body fluids |
Non-Patent Citations (2)
| Title |
|---|
| 唐家宏等: "实时荧光定量PCR方法检测急性髓系白血病FLT3基因mRNA的表达", 《广东医学》, vol. 29, no. 3, 31 March 2008 (2008-03-31), pages 377 - 379 * |
| 张泽川等: "双重PCR检测急性髓系白血病FLT3-ITD和NPM1基因突变", 《中国实验血液学杂志》, vol. 19, no. 3, 20 June 2011 (2011-06-20) * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160056841A (en) * | 2014-11-12 | 2016-05-20 | 가톨릭대학교 산학협력단 | Method for quantitative analysis of FLT3 gene mutation and kit |
| KR102041001B1 (en) * | 2014-11-12 | 2019-11-06 | 가톨릭대학교 산학협력단 | Method for quantitative analysis of FLT3 gene mutation and kit |
| CN111433374A (en) * | 2017-12-01 | 2020-07-17 | 生命科技股份有限公司 | Method, system and computer readable medium for detecting tandem repeat region |
| US11961591B2 (en) | 2017-12-01 | 2024-04-16 | Life Technologies Corporation | Methods, systems, and computer-readable media for tandem duplication detection |
| CN108676876A (en) * | 2018-05-23 | 2018-10-19 | 苏州锐讯生物科技有限公司 | primer group for detecting mutant type F L T3-ITD based on digital PCR and application thereof |
| CN110241200A (en) * | 2019-06-18 | 2019-09-17 | 苏州大学附属第一医院 | High-sensitivity detection method and kit for FLT3-ITD mutation |
| CN110241200B (en) * | 2019-06-18 | 2024-01-12 | 苏州大学附属第一医院 | FLT3-ITD mutation high-sensitivity detection method and kit |
| CN110511983A (en) * | 2019-08-07 | 2019-11-29 | 南京实践医学检验有限公司 | Method based on capillary electrophoresis quantitative detection FLT3-ITD gene mutation |
| CN111719005A (en) * | 2020-06-29 | 2020-09-29 | 天津拓瑞医药科技有限公司 | PCR detection method for mycoplasma feline haemophilus |
| CN113718020A (en) * | 2021-09-13 | 2021-11-30 | 广东永诺医疗科技有限公司 | Primer-probe combination and kit for detecting internal tandem repeat mutation of human leukemia FLT3 gene and application of primer-probe combination and kit |
| CN117568455A (en) * | 2024-01-03 | 2024-02-20 | 杭州宏望医学检验实验室有限公司 | Primer combinations, kits and methods for detecting leukemia fusion genes based on capillary electrophoresis fragment analysis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103103251A (en) | Kit for detecting FLT3-ITD (Fms-like tyrosine kinase 3-internal tandem duplication) gene mutation by using fluorescence PCR (Polymerase Chain Reaction) capillary electrophoresis | |
| CN104099425B (en) | A kind of test kit for detecting B-raf transgenation | |
| CN104774962A (en) | Kit for detecting BRAF gene mutation and detecting method thereof | |
| CN104017887A (en) | Primer pair as well as probe and kit for detecting human BRAF gene mutation | |
| CN102586401A (en) | Method and kit for detecting mutation of BRAF gene of human colorectal cancer | |
| CN105420361B (en) | Method and kit based on digestion Sensitive Detection human EGFR gene mutations | |
| CN104357569A (en) | Method for detecting deafness mutant gene based on peptide nucleic acid (PNA)-clamped polymerase chain reaction (PCR) | |
| CN109022573A (en) | The combination of breast cancer PIK3CA hot spot mutation detection probe primer sequence and kit | |
| CN111808946B (en) | Myelodysplastic syndrome marker and kit thereof | |
| CN104774963A (en) | Kit for detecting PIK3CA gene mutation and detecting method thereof | |
| WO2020215313A1 (en) | Method and kit for detecting pd-l1 expression level | |
| CN102634572A (en) | Reagent kit for detecting mRNA (messenger ribonucleic acid) expression of fused gene E2A-PBX1 via fluorescent quantitative RT-PCR (reverse transcription-polymerase chain reaction) | |
| CN105838784B (en) | Application of the miR-99a as acute myeloid leukemia stem cell molecular marker | |
| CN102925560A (en) | Kit and method for detecting mutant alpha-Mediterranean anemia genes through HRM (high resolution melting) method | |
| CN113699276B (en) | New coronavirus 5 point mutation S gene identification kit based on high-resolution melting curve and its identification method | |
| CN102021228B (en) | Specific primers for tissue or whole blood EGFR gene mutation detection | |
| CN107058563A (en) | A kind of kit and its method for being used to detect peripheral blood EGFR gene T790M mutation | |
| CN108728538B (en) | ALK gene fusion detection primer, method and kit | |
| CN105969908A (en) | CTNNB1 third exon mutation detection primer probes and kit thereof | |
| CN114921531A (en) | Application of exosome RNA in curative effect evaluation of RTK inhibitor for treating advanced non-small cell lung cancer | |
| CN116814780A (en) | Early diagnosis of liver cancer based on gene methylation, protein, and/or miRNA markers | |
| CN107653304A (en) | A kind of amplimer, sequencing primer, kit and method for being used to detect KRAS gene mutation | |
| CN101781678A (en) | Kit for detecting fusion gene Bcl2-IgH rearrangement | |
| CN112210606A (en) | Digital PCR detection system for EGFR T790M locus and application thereof | |
| CN112430646A (en) | EGFR gene amplification detection method based on digital PCR platform |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130515 |